Robotic/laparoscopic prolapse repair and the role of hysteropexy: A urology perspective, "Beyond the Abstract," by Daniel S. Elliott, MD ...

BOND-003 Trial: Cretostimogene Grenadenorepvec Shows Promise in BCG-Unresponsive NMIBC - Mark Tyson Breaking Paradigms: BOND-003's Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive Non-Muscle ...

(UroToday.com) The 2024 GU ASCO annual meeting featured a session on the role of immunotherapy in advanced urothelial carcinoma and a presentation by Dr. Peter O'Donnell discussing drug sequencing, ...

Phase 3 Trial Results for Intravesical Cretostimogene Grenadenorepvec in Bladder Cancer - Mark Tyson CORE-008 Trial Cohort CX: Combining Cretostimogene Grenadenorepvec and Gemcitabine for Bladder ...

Amy Pearlman discusses penile rehabilitation strategies following prostate cancer treatment. Dr. Pearlman shares her expertise on vacuum pump therapy as a crucial component of penile rehabilitation.

Jason Efstathiou about the results of the PARTIQoL Trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou reveals that the study found no ...

Alicia Morgans interviews Praful Ravi about his abstract presentation concerning PSA nadir within the ICECaP data set. ICECaP, a comprehensive data repository of individual patient data from more than ...

Read the Full Video Transcript Diane Newman: Welcome to UroToday's Bladder Health Center of Excellence. I am Diane Newman, the center's Editor, and Adjunct Professor of Urology and Surgery at the ...

Prostate cancer, while commonly diagnosed in early forms, remains the second leading cause of cancer mortality in the United States and Europe. 1 For patients who die of prostate cancer, some will be ...

Read the Full Video Transcript Rashid Sayyid: Hello, everyone, and thank you for joining us today in this UroToday recording. I'm Rashid Sayyid, robotic urology and oncology fellow at USC, and I'm ...

Giulia Marvaso discusses the RADIOSA trial, a phase II randomized study comparing SBRT alone versus SBRT with short-course hormonal therapy for oligorecurrent prostate cancer. The trial includes 102 ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.